Mutagenic Assessment of Olmesartan Cilexetil by Bacterial Mutation Assay |
Kim, Ji Won
(Department of Pharmacology, CKD Research Institute)
Ahn, Ilyoung (Toxicological Screening and Testing Division, National Institute of Food and Drug Safety Evaluation) Ryu, Sung Ha (College of Pharmacy, Dankook University) Jeon, Hong Ryeol (CTC BIO Inc.) Lee, Bong Sang (CTC BIO Inc.) Kim, Kyu-Bong (College of Pharmacy, Dankook University) |
1 | He, J. and Whelton, P.K. (1997) Epidemiology and prevention of hypertension. Med. Clin. North Am., 81, 1077-1097. DOI ScienceOn |
2 | Whelton, P.K. (1994) Epidemiology of hypertension. Lancet, 344, 101-106. DOI ScienceOn |
3 | Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K. and He, J. (2005) Global burden of hypertension: analysis of worldwide data. Lancet, 365, 217-223. DOI ScienceOn |
4 | Brunner, H.R. (2006) Olmesartan medoxomil: current status of its use in monotherapy. Vasc. Health Risk Manage., 2, 327-340. DOI |
5 | Fletcher, A.E., Palmer, A.J. and Bulpitt, C.J. (1994) Cough with angiotensin converting enzyme inhibitors: how much of a problem? J. Hypertens. Suppl., 12, S43-S47. |
6 | Vleeming, W., van Amsterdam, J.G., Stricker, B.H. and de Wildt, D.J. (1998) ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf., 18, 171-188. DOI ScienceOn |
7 | Warner, G.T. and Jarvis, B. (2002) Olmesartan medoxomil. Drugs, 62, 1354-1356. DOI ScienceOn |
8 | Mizuno, M., Sada, T., Ikeda, M., Fukuda, N., Miyamoto, M., Yanagisawa, H. and Koike, H. (1995) Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol., 285, 181-188. DOI ScienceOn |
9 | OECD/OCDE. (1997) OECD guidelines for the testing of chemicals (No. 471), Bacterial Reverse Mutation Test, pp. 1-11. |
10 | Norwood, D., Branch, E.I., Smith, B. and Honeywell, M. (2002) Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast., 27, 611-618. |
11 | Schwocho, L.R. and Masonson, H.N. (2001). Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J. Clin. Pharmacol., 41, 515-527. DOI ScienceOn |
12 | Puchler, K., Nussberger, J., Laeis, P., Wittem, P.U. and Brunner, H.R. (1997) Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist in saltrestricted hypertensive patients. J. Hypertens., 15, 1809-1812. DOI |
13 | Brambilla, G. and Martelli, A. (2006) Genotoxicity and carcinogenicity studies of antihypertensive agents. Mutat. Res., 612, 115-149. DOI ScienceOn |
![]() |